Understanding Congenital Heart Defects in Individuals with Down Syndrome
February is Heart Month, a time to bring awareness to heart conditions. Congenital Heart Defects affect approximately 50% of babies
February 20, 2022
February is Heart Month, a time to bring awareness to heart conditions. Congenital Heart Defects affect approximately 50% of babies
Detection of any cognitive impairment as part of the Affordable Care Act’s annual wellness visit in primary or other health
EXAMINING ADULTS WITH NEUROATYPICAL CONDITIONS FOR MCI/DEMENTIA DURING COGNITIVE IMPAIRMENT ASSESSMENTS: REPORT OF THE NEUROATYPICAL CONDITIONS EXPERT CONSULTATIVE PANEL July,
February is Heart Month, a time to bring awareness to heart conditions. Congenital Heart Defects affect approximately 50% of babies
[divider line_type=”No Line”][/vc_row]February is Heart Month, a time to bring awareness to heart conditions. Congenital Heart Defects affect approximately 50%
RELIABLE DOWN SYNDROME RESOURCES FOR EVERY FAMILY, FOR EVERY STAGE OF LIFE “Down syndrome research is of huge importance to
Sleep disorders frequently affect individuals with Down syndrome. Growing evidence suggests that sleep disruption may also accelerate the progression to
Date: 2/7/2022
People with Down syndrome are far more likely than the general population to have an Alzheimer’s diagnosis by age 65, so access to a new class of Alzheimer’s drugs could not only help those with a current diagnosis but would also generate new data on the efficacy of this type of drug in people with Down syndrome. The CMS decision, if enacted, will place insurmountable roadblocks on the path to future treatment possibilities for anyone with a Down syndrome diagnosis.
This decision, if enacted, openly discriminates against people with Down syndrome, a group of people who have not been included in any of the previous or current clinical trials on Aduhelm or the other monoclonal anti-amyloid antibodies.
Read more about LuMind IDSC’s official statement on the CMS decision.
Sometimes falling asleep and having a restful night isn’t as easy as we would hope. In some cases, sleeplessness can
Date: 2/7/2022
People with Down syndrome are far more likely than the general population to have an Alzheimer’s diagnosis by age 65, so access to a new class of Alzheimer’s drugs could not only help those with a current diagnosis but would also generate new data on the efficacy of this type of drug in people with Down syndrome. The CMS decision, if enacted, will place insurmountable roadblocks on the path to future treatment possibilities for anyone with a Down syndrome diagnosis.
This decision, if enacted, openly discriminates against people with Down syndrome, a group of people who have not been included in any of the previous or current clinical trials on Aduhelm or the other monoclonal anti-amyloid antibodies.
Read more about LuMind IDSC’s official statement on the CMS decision.